Exciting new cancer centre opens offering faster treatment
An exciting new development extending world class standards of cancer care to even more patients opens today (Wed, April 28).
This is The Royal Marsden Private Care’s new diagnostic and treatment centre in central London.
The Royal Marsden has expanded its Private Care service with the official opening of the brand new, research-led, diagnostic outpatient and treatment facility in Cavendish Square.
Located in the heart of the capital’s world-renowned and most respected healthcare district between Oxford Street and Harley Street, the new facility offers world leading standards of cancer care to patients in a calm, modern and reassuring environment.
Fast and direct access to world-class experts
Housed within an Edwardian listed building, Cavendish Square is a dedicated and comprehensive cancer diagnostic and treatment centre.
It offers patients fast and direct access to The Royal Marsden’s world-leading diagnostic and research-active consultants specialising in a full range of cancer services.
Home to a state-of-the-art diagnostic imaging suite offering MRI, CT, X-Ray, ultrasound and mammography, experts will be able to identify and diagnose cancers earlier across all the main tumour types with other clinical specialties offered including genetics, plastic surgery and reconstruction and pain management.
A one-stop diagnostic service will be offered at the centre where patients can expect to have an appointment booked following their initial enquiry, direct access to diagnostic services, same day scans and test results.
The centre is also home to a minor procedure suite and a medical day unit with bespoke treatment bays, which will provide the highest level of patient focused care for UK and overseas patients who are receiving some of the most advanced cancer treatments.
Cavendish Square will initially see both Private Care and NHS patients ensuring that all patients with suspected cancer receive quick access to diagnostic tests.
Unique model with revenues reinvested in NHS care
The centre will also contribute to the financial sustainability of The Royal Marsden, ensuring all patients benefit as part of the unique, integrated partnership between The Royal Marsden’s NHS and Private Care services.
This model means revenue generated from Private Care is reinvested back into the NHS Foundation Trust, ensuring that all patients can be offered the highest standards of cancer treatment and care.
As Clinical Director of the new facility, I am very much looking forward to welcoming patents to Cavendish Square.
Targeted and personalised approach
The Royal Marsden sees and treats 60,000 NHS and private patients every year and Cavendish Square is an exciting new development that will allow our multidisciplinary teams to offer world class standards of cancer care to even more patients, diagnosing cancers faster with a targeted and personalised approach.
Best of both worlds
My colleague Shams Maladwala, Managing Director of The Royal Marsden Private Care, says: “Improving patient access to better and more rapid diagnostics is a priority at The Royal Marsden, and Cavendish Square is part of a broader strategy to diagnose cancer faster and earlier.
“Thanks to our integrated model, patients seeking the very best private cancer treatment can do so safe in the knowledge that it is backed by the strictest safety standards and governance usually only seen in the NHS.”
“Further investment in the Trust’s NHS services from Private Care revenue provides the best of both worlds for both patients and clinicians, supporting The Royal Marsden in continuing to be worldwide leaders in the field of cancer diagnosis, treatment, care, research and education.”
It is reported that The Royal Marsden has by far the highest private patient revenues in the NHS, reaching £132.6m in 2019-20 – 20% of the NHS total.
Further coverage is available at The Independent Practitioner and The Financial Times.
For more information about Prof Nutting's work please visit the CV page, get in touch or arrange a consultation.